175 related articles for article (PubMed ID: 38831433)
1. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
[TBL] [Abstract][Full Text] [Related]
2. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
Hong P; Han L; Wan Y
Eur J Pain; 2024 Jul; 28(6):978-986. PubMed ID: 38183343
[TBL] [Abstract][Full Text] [Related]
3. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
4. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
5. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
6. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
[TBL] [Abstract][Full Text] [Related]
7. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
[TBL] [Abstract][Full Text] [Related]
8. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
9. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
10. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
11. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
Miao L; Miao T; Zhang Y; Hao J
BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
[TBL] [Abstract][Full Text] [Related]
12. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
13. Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.
Harrison SC; Holmes MV; Burgess S; Asselbergs FW; Jones GT; Baas AF; van 't Hof FN; de Bakker PIW; Blankensteijn JD; Powell JT; Saratzis A; de Borst GJ; Swerdlow DI; van der Graaf Y; van Rij AM; Carey DJ; Elmore JR; Tromp G; Kuivaniemi H; Sayers RD; Samani NJ; Bown MJ; Humphries SE
JAMA Cardiol; 2018 Jan; 3(1):26-33. PubMed ID: 29188294
[TBL] [Abstract][Full Text] [Related]
14. Lipid lowering and Alzheimer disease risk: A mendelian randomization study.
Williams DM; Finan C; Schmidt AF; Burgess S; Hingorani AD
Ann Neurol; 2020 Jan; 87(1):30-39. PubMed ID: 31714636
[TBL] [Abstract][Full Text] [Related]
15. Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study.
Tao H; Yu Z; Dong Y; Liu L; Peng L; Chen X
Front Immunol; 2023; 14():1160312. PubMed ID: 37350960
[TBL] [Abstract][Full Text] [Related]
16. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
17. The causal effects of lipid traits on kidney function in Africans: bidirectional and multivariable Mendelian-randomization study.
Kintu C; Soremekun O; Kamiza AB; Kalungi A; Mayanja R; Kalyesubula R; Bagaya S B; Jjingo D; Fabian J; Gill D; Nyirenda M; Nitsch D; Chikowore T; Fatumo S
EBioMedicine; 2023 Apr; 90():104537. PubMed ID: 37001235
[TBL] [Abstract][Full Text] [Related]
18. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.
Richardson TG; Sanderson E; Palmer TM; Ala-Korpela M; Ference BA; Davey Smith G; Holmes MV
PLoS Med; 2020 Mar; 17(3):e1003062. PubMed ID: 32203549
[TBL] [Abstract][Full Text] [Related]
20. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
